Health

The case for investing in harm reduction in Eastern Europe and Central Asia

March 10, 2021

Global

The case for investing in harm reduction in Eastern Europe and Central Asia

March 10, 2021

Global
Dr Chrissy Bishop

Former Associate, Health policy and clinical evidence

Chrissy currently serves as a Strategy and Policy Senior Manager with NHS England but was formerly an associate in Economist Impact's Health Policy and Clinical Evidence team. During her tenure at Economist Impact, Chrissy’s role involved rapid reviews of scientific papers and underlying health news reports as well as critical appraisals of scientific papers for audiences such as NHS commissioners, and the European Food Information Council. Chrissy also designed and worked on longer-term research assignments across the health market from industry to academia, regulators and payers, uniting specialist methods in both epidemiological and economic modelling.

Chrissy has an undergraduate degree in Occupational Therapy from York St John University, and two MSc degrees. The first MSc in Professional Health and Social Care from York St John University and the second in Epidemiology and Biostatistics from the University of Leeds. Chrissy was awarded a National Institute for Health Research scholarship to pursue a doctorate investigating the healthcare needs of children with chronic conditions in multi-ethnic communities. She received her doctorate in March 2019 from the University of Bradford. Chrissy worked as a Senior Occupational Therapist in the NHS and an Operations Manager for a private health care company before joining the Health Policy and Clinical Evidence team.

The case for investing in harm reduction in Eastern Europe and Central Asia

Inforaphic Mobile Image

The case for investing in harm reduction in Eastern Europe and Central Asia

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week